All three tenses have at least two readings, so the archetype blend applies as printed.
All nine metrics read as filed from the record.
What did they actually do?
Has it survived what it has been through?
8 warning events since 2017; the latest 2022-01-18.
From the record
Bausch Health Companies Inc's filings since 2017 show 8 warning events: a debt default or acceleration notice (8-K item 2.04, 8 times, the latest 2022-01-18) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+0.7% a year over 10 filed years; profitable in 2 of 10.
From the record
Bausch Health Companies Inc's 10 filed years say what it did: revenue went from $9.7 billion in fiscal 2016 to $10 billion in fiscal 2025, up 0.7% a year; it rose in 5 of 9 years; the deepest fall was 17% from fiscal 2016 to fiscal 2020; net income was positive in 2 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
Share count grew 1.2% a year. 0% of cash flow returned. Insiders: 5 sales, 0 purchases.
From the record
Over the 3 fiscal years to 2025-12-31, Bausch Health Companies Inc's diluted share count grew about 1.2% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 5 sales (5 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-10-02 (their Form 4 filings).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they doing right now?
Is it financially healthy right now?
ROE 32%: 32¢ of profit per shareholder dollar. Leverage 99%: owes 99¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Bausch Health Companies Inc earned about 32 cents of profit for every dollar of shareholders' money. Leverage: it owed about 99 cents per dollar of assets, and net share issuance: its share count grew 1.9% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 26% of 315 in its family; net margin 1.2%.
From the record
Bausch Health Companies Inc's standing among 315 graded names in its industry family: revenue of $10 billion in fiscal 2025 ranks in the top 5% by size; a net margin of 1.2% ranks in the top 23%; revenue growth of 8.1% a year over the last 3 filed years ranks in the bottom 49% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 32% of 315 in its family for leadership; chief executive since 2021.
From the record
Bausch Health Companies Inc's leadership, from its insiders' filings and its current reports: the chief executive on the record is Appio, Thomas (Chief Executive Officer, as filed), filing under that title since 2021-12-30, 4.9 years (bottom 47% of its family); the 14 officers and directors filing in the last fifteen months have been on the record a median of 2.5 years (bottom 11%); 8 officer or director changes were reported on Form 8-K since 2023-11-13, against the 14 people in charge now (bottom 37%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 29% of 273 in its family for room to expand.
From the record
Bausch Health Companies Inc's room to grow, from the newest filed statements (fiscal 2025): cash of $1.3 billion against debt of $21 billion leaves -73.1% of its assets as net cash, bottom 1% of its family; cash from operations less capital spending is 9.8% of revenue (top 22%); research spending of 6.1% of revenue (bottom 7%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 35% of 306 in its family for growth drivers.
From the record
Bausch Health Companies Inc's growth drivers, from the filed years to fiscal 2025: revenue grew 8.1% a year over the last three filed years against 0.7% over all 10, speeding up (top 20% of its family); the newest year grew 6.7% (bottom 49%); research spending grew 5.9% a year (top 45%); capital spending grew 22.1% a year (top 24%) (its annual reports). Bausch Health Companies Inc reported 3 product lines in fiscal 2025: Product at $10 billion (99%), Product and Service Other at $110 million (1%), Price Appreciation Credit at $18 million (0%); 2 of 3 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 40% of 233 in its family for expectations against reality.
From the record
Bausch Health Companies Inc's newest year against its own record: revenue of $10 billion in fiscal 2025 came in 2% below the $10 billion its prior three years' pace pointed to (bottom 49% of its family); net income of $120 million against a prior three-year average of $298 million (top 12%); a net margin of 1.2% against -3.4% before (bottom 42%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made